Clinical Gastroenterology and Hepatology Impact Factor

That places CGH in roughly the top 6% of its JCR category by current rank.

The headline number is strong, but the more revealing metric here is the JCI of 2.81. That means CGH is performing well above category average after normalization, which matters because gastroenterology contains journals with very different citation cultures.

So the journal is not just coasting on volume or on being tied to the AGA brand. The citation profile says clinicians and researchers are using what gets published here.

The journal's identity matters too. CGH is a clinical-practice journal. A 16.2 JIF in that lane means the journal is rewarding manuscripts that actually change how gastroenterologists and hepatologists read evidence, not just mechanistic GI biology with a clinical sentence bolted on at the end.

The author-planning implication is straightforward: CGH is rarely won by prestige logic alone. A manuscript has to show what a gastroenterologist, hepatologist, endoscopist, or clinical researcher should interpret differently after reading it. If the abstract says "clinical relevance" but the methods, outcomes, and tables only support a local association, the impact factor can make the target look cleaner than it is.

The JCR row above is the authoritative impact factor on this page. Use the Scopus impact-score sequence below as an open-citation context check for CGH's clinical GI readership.

Directionally, the open citation signal is up from 5.19 in 2023 to 5.95 in 2024, and well above the mid-2010s band. That is consistent with CGH's stronger role in contemporary GI practice, especially for translational clinical work, outcomes research, endoscopy, and studies with immediate patient-care relevance.

The key point is that CGH has become harder to treat as a simple second-choice journal. Its own citation profile is strong enough that fit now matters a lot.

The table below separates the current JCR placement from older public context. Use the current JCR row for impact-factor decisions; use publisher and directory pages as supporting context only when they match the same release year.

The mistake is to see a double-digit JIF and assume CGH is just a lower-significance version of Gastroenterology or Gut.

That is not the cleanest frame. CGH usually rewards papers that are:

• clinically useful now

• focused on GI and liver practice

• strong enough methodologically to change interpretation or management

• written for clinicians rather than primarily for mechanistic readers

That means some papers rejected from a flagship GI journal really do belong here. But some papers that look weaker by prestige logic still do not fit if they are not immediately practice-relevant.

Across our Clinical Gastroenterology and Hepatology pre-submission reviews, the recurring misses are usually easy to name after the fact: the authors say the work is clinically important, but the manuscript does not make the practice consequence legible enough for an editor to route it quickly. CGH tends to reward papers that answer a live GI clinical question in a way readers can actually use.

Four failure patterns recur.

Clinical Gastroenterology and Hepatology clinical relevance statement that is generic. The manuscript says the condition matters, but not what gastroenterologists should do differently after reading the paper. In CGH-targeted drafts, this often shows up when the abstract names colorectal cancer burden, inflammatory bowel disease prevalence, MASLD risk, or endoscopy utilization, but the Clinical Relevance Statement never identifies a decision, threshold, surveillance choice, diagnostic interpretation, or treatment implication.

Clinical Gastroenterology and Hepatology single-center evidence stretched too far. Editors often push back when the paper makes broad practice claims from a narrow cohort without validation or design features that justify the leap. The main tables may be statistically clean, but the sample source, referral pattern, missing-data strategy, and subgroup counts do not support the broad claim made in the abstract. CGH readers need to know whether the finding changes GI practice generally or only describes one local setting.

Clinical Gastroenterology and Hepatology mechanistic biology without patient-facing validation. Good GI biology does not automatically become CGH material if the patient-facing consequence is still indirect. We see this when organoid, microbiome, immune-signaling, or epithelial-barrier work carries the scientific weight, while the clinical bridge sits in the discussion. For CGH, the abstract and first results table should make the patient-facing consequence visible earlier.

Clinical Gastroenterology and Hepatology association without decision value. This is common in observational studies that show an association clearly but do not change diagnosis, stratification, treatment, or follow-up. The figure may be persuasive, but the paper still needs a practical answer: which patient group, clinical action, risk threshold, or interpretation changes because of the finding?

If that still sounds like the paper, a Clinical Gastroenterology and Hepatology submission readiness check is usually more useful than another round of formatting work.

Clinical Gastroenterology and Hepatology has an impact factor of 16.2 and a five-year JIF of 13.6. The stronger signal is that CGH now sits comfortably in the upper part of the GI clinical tier and has a high normalized citation profile.

If the paper is not immediately useful for GI practice, the metric will make the fit look better than it is.